Alzheimer’s Society

ADDF, Alzheimer’s Society U.K. to test erectile dysfunction drug as dementia treatment

Friday, December 12, 2014

The Alzheimer’s Drug Discovery Foundation (ADDF), based in New York, and the Alzheimer’s Society U.K. have announced new funding to explore the possibility of using a commonly prescribed drug which treats erectile dysfunction as the next treatment for dementia. Tadalafil—part of the same class of drugs as Viagra—is to be one of the major research programs funded by the two charities in a cross-Atlantic research partnership. This is the first ever study researching the use of an erectile dysfunction drug for vascular dementia.

[Read More]

Neuro-MAP, MRC Technology to jumpstart drug development for brain diseases

Wednesday, November 19, 2014

Drugs for brain diseases such as dementia, motor neurone disease and Parkinson’s, which have stalled in development, could be revived thanks to up to $47.1 million in funding and resources from a global coalition of charities and funders. The Neurodegeneration Medicines Acceleration Program (Neuro-MAP), led by U.K. medical research charity MRC Technology, will help charities and funding bodies identify promising drug projects no longer in development and help scientists take them forward to the next stage.

[Read More]

ADDF, Alzheimer’s Society partner on $3M initiative

Wednesday, January 29, 2014

The Alzheimer’s Drug Discovery Foundation (ADDF) and the Alzheimer’s Society (U.K.) have partnered to provide funding for research in Alzheimer’s disease and related dementias, with the goal of accelerating critical development programs and bringing new treatments to patients. The partnership intends to fund projects up to $1.5 million each, focused on drug repurposing, leveraging existing scientific evidence and research to accelerate the drug development process.

[Read More]